Peptide-based radiopharmaceutical Diatide of Londonderry, NH, raised $11.8 million last month through a placement of preferred stock to existing investors. The preferred stock is convertible into 1.2 million shares of Diatide common stock. Diatide
Peptide-based radiopharmaceutical Diatide of Londonderry, NH, raised $11.8 million last month through a placement of preferred stock to existing investors. The preferred stock is convertible into 1.2 million shares of Diatide common stock. Diatide executives said the funds would be used for intermediate-term financing needs, to move its late-stage products toward commercialization, and to increase R&D in the area of therapeutic agents.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.